CytomX Announces Management Team Changes
May 15 2017 - 4:01PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that Bob Goeltz, chief
financial officer, has decided to leave the company to pursue new
opportunities. In conjunction with Mr. Goeltz’s departure, CytomX
is appointing Debanjan Ray as chief financial officer and head of
corporate development, effective immediately. Mr. Ray has
been with CytomX since 2011, and most recently served as senior
vice president, corporate development and strategy. CytomX is also
promoting Danielle Olander to senior vice president, talent and
administrative operations.
“Bob has played a key role in our success at
CytomX, including leading our $92 million initial public offering
in 2015, and building a first-class financial organization. I want
to thank him for his many contributions and wish him well in future
endeavors,” said Sean McCarthy, D.Phil., president and chief
executive officer.
“During his six years with the company, Debanjan
has been instrumental to CytomX’s business success, including
structuring and executing collaborations that have resulted in more
than $300 million in upfront and milestone payments to date and
total potential deal value in excess of $5 billion. I am delighted
to have Debanjan assume the CFO role and look forward to continuing
to partner with him as we rapidly progress our pipeline of
potentially transformative Probody™ therapeutics,” continued Dr.
McCarthy. “I also congratulate Danielle on her very well-deserved
promotion that reflects her broad impact on our organizational
development.”
Mr. Ray has more than 15 years of experience in the
biopharmaceutical industry. Prior to joining CytomX in 2011, Mr.
Ray was vice president of business development at Itero
Biopharmaceuticals. Earlier in his career, Mr. Ray was an associate
director of business development at Portola Pharmaceuticals and
held positions in the life sciences venture practice at J.P. Morgan
Partners and McKinsey & Company. Mr. Ray holds a dual B.S. in
chemical engineering and biology from the Massachusetts Institute
of Technology and an M.B.A. from The Wharton School, University of
Pennsylvania.
Ms. Olander has led human resources management and
operations for more than 20 years and has been a member of the
CytomX team since 2014. Prior to CytomX, she served as the senior
director of human resources management at Portola Pharmaceuticals.
Prior to joining Portola, Ms. Olander held positions at SuperGen
(now Astex Pharmaceuticals), SUGEN (acquired by Pfizer) and Kinetic
Search. She received her B.S. in human resource management from
Colorado Technical University. She is chairperson of the
Biotechnology HR Network and an active member of the Society for
Human Resources Management and World at Work, The Total Rewards
Association.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused
biopharmaceutical company pioneering a novel class of
investigational antibody therapeutics based on its Probody
technology platform. The Company uses its platform to create
proprietary cancer immunotherapies against clinically-validated
targets, such as PD-L1, and develop first-in-class cancer
therapeutics against difficult-to-drug targets, such as CD166.
Probody therapeutics are designed to take advantage of unique
conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. The Company’s lead program, CX-072, a
wholly-owned PD-L1-targeting Probody therapeutic, is being
evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody
Clinical Assessment In Man), an international umbrella clinical
trial program that provides clinical trial sites with access to the
Company’s novel therapies under one central protocol. The trial
initiation for CX-2009, a first-in-class Probody drug conjugate
targeting the highly expressed tumor antigen, CD166, is expected
mid-2017. In addition to its proprietary programs, CytomX is
collaborating with strategic partners, including AbbVie,
Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
Media Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Elizabeth Broder
ebroder@troutgroup.com
646-378-2945
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024